The company develops procedures for regenerative medicine. For the prevention and treatment of human diseases, it researches and develops cell-based therapeutics and biopharmaceuticals, in particular for the activation of neogenesis in the context of cellular replacement therapy. The company can establish branches and subsidiaries in Switzerland and abroad, participate in other companies in Switzerland and abroad, and enter into all transactions and conclude contracts that may be related to the purpose of the company, including acquiring, holding and selling real estate.